Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-120 low-dose LSD for adult ADHD
2020-001098-55Phase 2Completed
- Sponsor
- MindMed
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing MM-120 with Placebo (2 arms). Primary endpoint: Change from baseline in AISRS total score at 6 weeks. Started May 2020; status: completed.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2020-001098-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001098-55.